antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-333Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR PRACTITIONERSЭффективность использования циклоферона в терапии хронического гепатита В (результаты рандомизированных многоцентровых исследований)Cycloferon Efficacy of Therapy of Chronic Hepatitis B (Results of Randomized Multicentre Study)СологубТ. В.SologubT. V.noemail@neicon.ruШульдяковА. А.ShuldyakovA. A.noemail@neicon.ruГорячеваЛ. Г.GoryachevaL. G.noemail@neicon.ruБарановаИ. П.BaranovaI. P.noemail@neicon.ruЛиньковаЮ. Н.LinkovaYU. N.noemail@neicon.ruКоваленкоА. Л.KovalenkoA. L.noemail@neicon.ruРоманцовМ. Г.RomantsovM. G.noemail@neicon.ruСанкт-Петербургская государственная медицинская академия им. И. И. МечниковаРоссияI. I. Mechnikov St.Petersburg State Medical AcademyRussian FederationСаратовский государственный медицинский университетРоссияSaratov State Medical UniversityRussian FederationНИИ детских инфекций ФМБА, Санкт-ПетербургРоссияResearch Institute of Children Infections, St.PetersburgRussian FederationПензенский Государственный институт усовершенствования врачейРоссияPenza State Institute of Postgraduate Medical TrainingRussian FederationНаучно-технологическая фармацевтическая фирма «ПОЛИСАН», Санкт-ПетербургРоссияResearch and Technological Pharmaceutical Co. POLYSAN, St.PetersburgRussian Federation201013052020559-103741Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/333

При лечении больных хроническим гепатитом В наилучший терапевтический эффект получен при включении в схему противовирусной терапии циклоферона. Полной стойкой ремиссии удалось достичь у 54,1% пациентов при комбинации циклоферона с ламивудином, а назначение а-интерферона с циклофероном обеспечило ремиссию 44,1% больным, резистентным к лечению ламивудином. Терапия хронического гепатита В с применением циклоферона позволяет уменьшить частоту и выраженность побочных явлений, препятствует формированию резистентности к ламивудину и появлению мутантных вирусов.

The best therapeutic effect in the treatment of patients with chronic hepatitis B was observed with the use of cycloferon in the scheme of the antiviral therapy. The combination of cycloferon with lamivudine provided complete stable remission in 54.1% of the patients, whereas the use of а-interferon in combination with cycloferon provided remission in 44.1% of the lamivudine-resistant patients. The use of cycloferon in the therapy of chronic hepatitis B made it possible to lower the frequency and manifestation level of the side effects and prevented the lamivudine resistance development and generation of the virus mutants.

хронический гепатит Вциклоферонchronic hepatitis BcycloferonReferencesOhata K., Hamasaki K., Toriyama K. et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis В virus infection. J Gastroenterol Hepatol 2004; 6: 670-675.Ohata K., Hamasaki K., Toriyama K. et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis В virus infection. J Gastroenterol Hepatol 2004; 6: 670-675.Kobayashl M., Suzuki F., Arase У. et al. Infection with hepatitis В virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004; 9: 39: 844-850.Kobayashl M., Suzuki F., Arase У. et al. Infection with hepatitis В virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004; 9: 39: 844-850.Norder H., Courouce A. M., Coursaget P. et al. Genetic diversity of hepatitis В virus strains-derived worldwide: genotypes, subgenotypes and HBsAg subtypes. Intervirology 2004; 6: 47: 289-309.Norder H., Courouce A. M., Coursaget P. et al. Genetic diversity of hepatitis В virus strains-derived worldwide: genotypes, subgenotypes and HBsAg subtypes. Intervirology 2004; 6: 47: 289-309.Hess G., Weber C., Rossol S. Treatment of hepatitis В surface antigen (HBsAg)-positive chronic hepatitis with recombinant alpha-A-interferon. Results of a phase II study. Z Gastroenterol 1988; 7: 26: 380-387.Hess G., Weber C., Rossol S. Treatment of hepatitis В surface antigen (HBsAg)-positive chronic hepatitis with recombinant alpha-A-interferon. Results of a phase II study. Z Gastroenterol 1988; 7: 26: 380-387.Asselah T., Castelnau C., Marcellin P. Treatment of chronic hepatitis В. Presse Med.2004; 2: 327-334.Asselah T., Castelnau C., Marcellin P. Treatment of chronic hepatitis В. Presse Med.2004; 2: 327-334.Danalioglu A., Kaymakoglu S., Cakaloglu Y. et al. Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B. Int. J Clin Pract 2004; 7: 58: 659-661.Danalioglu A., Kaymakoglu S., Cakaloglu Y. et al. Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B. Int. J Clin Pract 2004; 7: 58: 659-661.Farell G. C., Teoh N. C. Management of chronic hepatitis В virus infection: a new era of disease control. Int Med J 2006; 2: 36: 100-113.Farell G. C., Teoh N. C. Management of chronic hepatitis В virus infection: a new era of disease control. Int Med J 2006; 2: 36: 100-113.Foldes I., David K., Horvath G. et al. Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha. Orv Hetil 2004; 23: 145: 1211-1216.Foldes I., David K., Horvath G. et al. Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha. Orv Hetil 2004; 23: 145: 1211-1216.Jang M. K., Chung Y. H., Choi M. H. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 12: 19: 1363-1368.Jang M. K., Chung Y. H., Choi M. H. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 12: 19: 1363-1368.Kaygusuz I., Ozturk Kaygusuz T., Ozturk A. Effects of interferon-alpha2b on hearing. Int J Audiol 2004; 8: 43: 438-441.Kaygusuz I., Ozturk Kaygusuz T., Ozturk A. Effects of interferon-alpha2b on hearing. Int J Audiol 2004; 8: 43: 438-441.Lau G. K., Piratvisuth T., Luo T. H. et al. Peginterferon alfa-2a, lamivu-dine, and combination for HBEag-positive chronic hepatitis B. N Engl J Med 2005; 26: 352: 2682-2695.Lau G. K., Piratvisuth T., Luo T. H. et al. Peginterferon alfa-2a, lamivu-dine, and combination for HBEag-positive chronic hepatitis B. N Engl J Med 2005; 26: 352: 2682-2695.Marcellin P., Boyer N., Asselah T. Medical therapy of patients affected by HBe-Ag-negative chronic hepatitis B. Minerva Gastroenterol. Dietol 2006; 1: 52: 23-38.Marcellin P., Boyer N., Asselah T. Medical therapy of patients affected by HBe-Ag-negative chronic hepatitis B. Minerva Gastroenterol. Dietol 2006; 1: 52: 23-38.Milkiwitz P., Yim C., Pache I. et al. Diffuse skin reaction in patients with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol 2005; 11: 19: 677-678.Milkiwitz P., Yim C., Pache I. et al. Diffuse skin reaction in patients with hepatitis B, treated with two different formulations of pegylated interferon. Can J Gastroenterol 2005; 11: 19: 677-678.Liaw Y. F., Chien R. N., Yeh C. T. No benefit to continue lamivudine therapy after emergence of YMDE mutations. Antivir Ther 2004; 2: 9: 257-262.Liaw Y. F., Chien R. N., Yeh C. T. No benefit to continue lamivudine therapy after emergence of YMDE mutations. Antivir Ther 2004; 2: 9: 257-262.Kiyosawa К., Tanaka E. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B. J Gastroenterol 2001; 2: 38: 139-141.Kiyosawa К., Tanaka E. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B. J Gastroenterol 2001; 2: 38: 139-141.Tazulakhova E. J., Parshina O. V., Guseva T. S., Ershov F. J. Russian experience in screening, analysis, and clinical application of novel interferon inducers. J Interferon Cytokine Res 2001; 2: 21: 65-73.Tazulakhova E. J., Parshina O. V., Guseva T. S., Ershov F. J. Russian experience in screening, analysis, and clinical application of novel interferon inducers. J Interferon Cytokine Res 2001; 2: 21: 65-73.Zarubaev V. V., Slita A. Y., Krivitskaya V. Z. et al. Direct antiviral effects of cycloferon (10-carboxymeth-yl-9-acridanone) against adenovirus type 6. Antiviral Res 2003; 2: 58: 131-137.Zarubaev V. V., Slita A. Y., Krivitskaya V. Z. et al. Direct antiviral effects of cycloferon (10-carboxymeth-yl-9-acridanone) against adenovirus type 6. Antiviral Res 2003; 2: 58: 131-137.Авксентьева М. В., Воробьев П. A., Герасимов В. Б. и др. Экономическая оценка эффективности лекарственной терапии (фармако-экономический анализ). М.: 2000.Авксентьева М. В., Воробьев П. A., Герасимов В. Б. и др. Экономическая оценка эффективности лекарственной терапии (фармако-экономический анализ). М.: 2000.Ершов Ф. И., Киселев О. И. Интерфероны и их индукторы (от молекул до лекарств). М.: 2005.Ершов Ф. И., Киселев О. И. Интерфероны и их индукторы (от молекул до лекарств). М.: 2005.

The authors declare that there are no conflicts of interest present.